Back to Congress Materials and Publications

Note: The following publications may contain information that is not consistent with the approved prescribing information for resmetirom. These publications do not constitute a recommendation for use outside of country-specific labeling.

Download all
  • AASLD 2026 - HEOR
TitleDescriptionDownload
A 12-Month Real-World Assessment of Clinical Characteristics and Biomarker Changes Following Resmetirom Initiation in Patients with MASH: A Descriptive Cohort Study Using Electronic Medical Records in the United States

Poster Presentation

 DownloadPreview
Association of GLP-1 Use and End-Stage Liver Disease Events in US Adults with Metabolic Dysfunction-Associated Steatohepatitis

Poster Presentation

 DownloadPreview
Demographic, Clinical, and Medication Use Profiles of Patients Prescribed Resmetirom: A US Claims-Based Analysis

Poster Presentation

 DownloadPreview
Estimating Real-World Clinical and Economic Implications of GLP-1 Persistence and Dosing in Metabolic Dysfunction-Associated Steatohepatitis (MASH)

Poster Presentation

 DownloadPreview
Leveraging a System-Level Provider-Facing Fibrosis Dashboard: Signaling the Need for a MASH Quality Measure

Poster Presentation

 DownloadPreview
Patient Characteristics and Changes in Liver Function Laboratory Tests Among Resmetirom-Treated Patients in a Real-World MASH Population

Poster Presentation

 DownloadPreview
Real-World Characteristics, Treatment Patterns, and Clinical Outcomes Among Patients with MASH Initiating Resmetirom

Poster Presentation

 DownloadPreview
Real-World Characteristics and Clinical Effectiveness Outcomes Among Patients with MASH Initiating Resmetirom

Poster Presentation

 DownloadPreview
Real-World Medication Adherence and Persistence to Resmetirom in Patients with MASH

Poster Presentation

 DownloadPreview
Treatment Continuity with Resmetirom: A Real-World Studyt of Adherance abd Persistence in Metabolic Dysfunction-Associated Steatohepatitis (MASH)

Poster Presentation

 DownloadPreview
1 2
Download all
  • AASLD 2026 - Clinical
TitleDescriptionDownload
Impact of Resmetirom on Health-Related Quality of Life, Work Productivity, and Disease-Specific Symptoms in Compensated MASH Cirrhosis

Poster Presentation

 DownloadPreview
In F0-F1 and F2-F3 MASH, ≥5% Weight Loss Significantly Lowers VCTE and ELF Independent of Biopsy Fibrosis Improvement; Resmetirom and not Placebo Reduction of ELF and VCTE are Associated with Biopsy Improvement of Fibrosis, Independent of Weight Loss

Poster Presentation

 DownloadPreview
Reducing CV Risk in Patients with MASH Independent of Baseline Statin Use: Lp(a) and LDL-C Lowering by Resmetirom

Poster Presentation

 DownloadPreview
Treatment with Resmetirom Improves Symptom Burden in Patients with Metabolic Dysfunction-Associated Steatohepatitis (MASH)

Poster Presentation

 DownloadPreview
Updated Early and Week 52 Biomarker (MRI-PDFF, ALT, MRE, and PRO-C3) Responses to Resmetirom Associate with Improvements in MASH and Liver Fibrosis

Poster Presentation

 DownloadPreview